ArticlePharmacogenomics2017
Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.
Article in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- General practitioners' (GPs) experience, attitudes and needs on clinical genetic services: a systematic review.Family medicine and community health · 2022Pooled it
- Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.Clinical pharmacology and therapeutics · 2019Pooled it
- Implementation of Pharmacogenomics Testing in Daily Clinical Practice: Perspectives of Prescribers from Two Canadian Armed Forces Medical Clinics.Journal of personalized medicine · 2025Article
- Article
- Pharmacogenomic curriculum in Australian medical schools: a content analysis study.Pharmacogenomics · 2024Article
- Article
- Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.Frontiers in pharmacology · 2024Article
- Public perceptions of pharmacogenomic services in Ireland - Are people with chronic disease more likely to want service availability than those without? A questionnaire study.Exploratory research in clinical and social pharmacy · 2022Article
- Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models.Pharmacogenomics · 2021Review
- Multi-Institutional Implementation of Clinical Decision Support forJournal of personalized medicine · 2021Article
- Assessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics.Journal of the American College of Clinical Pharmacy : JACCP · 2021Article
- The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Article
- Implementation and obstacles of pharmacogenetics in clinical practice: An international survey.British journal of clinical pharmacology · 2019Article
- The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report From New Zealand.Frontiers in psychiatry · 2019Article
- Current landscape of personalized medicine adoption and implementation in Southeast Asia.BMC medical genomics · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
aimTo investigate provider utilization of pharmacist support in the delivery of pharmacogenetic testing in a primary care setting.
methodsTwo primary care clinics within Duke University Health System participated in the study between December 2012 and July 2013. One clinic was provided with an in-house pharmacist and the second clinic had an on-call pharmacist.
resultsProviders in the in-house pharmacist arm consulted with the pharmacist for 13 of 15 cases, or about one of every four patients tested compared with one of every 7.5 patients in the on-call pharmacist arm. A total of 63 tests were ordered, 48 by providers in the pharmacist-in-house arm.
conclusionThese findings suggest that the availability of an in-house pharmacist increases the likelihood of pharmacogenetic test utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.